Both worlds over time
Technical and news signals of the last 90 days on one timeline.
VST fundamental outlook?
From news analysis — different time windows than the trading horizons above
- VST trades at ~14x forward earnings, 33-47% below consensus, with a median analyst price target of $219 implying ~45% upside.
- CEO James Burke's $903K insider purchase at $135.49 signals confidence; analysts maintain Strong Buy with 43.6% upside.
- AI-driven power demand narrative strengthened by 20-year PPAs with Amazon, Meta, and New Era Energy, plus a JV with NVIDIA, KKR, and Kuwait Investment Authority.
- Execution risks: Q2 net income slipped 6.7% to $305M, FCF declined, and Moss Landing disruptions create near-term overhang.
- Legislative tailwind: House-passed Ratepayer Protection Act supports nuclear/SMR stocks, benefiting Vistra's 6.5 GW nuclear fleet.
Over the past month, VST has been driven by a mix of AI-driven power demand narratives and specific corporate developments. The most recent signal (Oct 8) is a bullish patent allowance for portfolio company Insu Therapeutics, boosting sentiment. Earlier, a series of mid-term signals highlighted Vistra's strategic positioning: a 20-year PPA with New Era Energy (5% non-voting interest), a JV with NVIDIA/KKR/KIA, and new 20-year deals with Amazon and Meta. The stock trades at ~14x forward earnings, 33-47% below consensus, with a median analyst price target of $219 (44.9% upside). CEO insider buying at $135.49 adds confidence. However, neutral signals flag execution risks: Q2 net income slipped 6.7% to $305M, FCF declined, and Moss Landing disruptions. The House-passed Ratepayer Protection Act and Anthropic IPO are structural tailwinds. Overall, the narrative is strongly bullish on AI-driven power demand, but near-term execution and valuation concerns temper conviction.
17 days ago · Based on 11 signals
What is being reported about VST
📝 Overview Generated automatically?
VST has been the subject of 11 signals across 11 articles in the last 365 days. Sentiment skews Bullish (64%).
Breakdown: 7 bullish, 0 bearish, 4 neutral. AI confidence averages 59% across all signals.
Most-cited catalysts: U.S. patent allowance for Insu Therapeutics' platform (1×), Exclusive worldwide UBC license (1×). Most-cited risk factors: Dependence on the commercial success of portfolio companies (1×), Regulatory hurdles in the pharmaceutical distribution space (1×).
Related assets
Same category or comparable signal picture — each card opens the full cockpit.